The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer
- Explore the impact of treatment with an aromatase inhibitor on the cognitive function
of postmenopausal women with stage I-III breast cancer vs in cancer-free, age-matched
OUTLINE: Patients receive adjuvant anastrozole or letrozole in the absence of disease
progression or unacceptable toxicity.
Patients and healthy volunteers undergo cognitive function testing consisting of
neuropsychological battery tests and complete self-reported questionnaires (e.g., Squire
Memory Self-Rating Questionnaire, and FACT-B Quality of Life Measure) regarding cognitive
ability, quality of life, fatigue, and psychosocial status. Patients and healthy volunteers
also undergo geriatric assessment at baseline and after 6 months of initiation with
aromatase inhibitor therapy.
Observational Model: Case Control, Time Perspective: Prospective
Impact of treatment with an aromatase inhibitor on cognitive function
Prior to starting aromatase treatment and 6 months after starting the medication.
Arti Hurria, MD
Beckman Research Institute
United States: Institutional Review Board
|City of Hope Comprehensive Cancer Center||Duarte, California 91010|